$0.110
-0.012 (-11.30%)At close
ARAY News
ARAY Events
Accuray Trading Halted, News Pending
Accuray trading halted, news pending
Accuray Approves 1-for-40 Reverse Stock Split
Accuray announced that its Board of Directors has approved a 1-for-40 reverse stock split of the company's common stock and a corresponding decrease to the authorized number of shares of common stock. The reverse stock split is intended to increase the per-share trading price of the company's common stock and enable the company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The reverse stock split will become effective at 12:02 a.m. Eastern Time on November 9, 2026. The company's common stock is expected to begin trading on a split-adjusted basis when the Nasdaq market opens on November 9, 2026 under the company's existing trading symbol, "ARAY," with a new CUSIP number of 004397 303.
Accuray Appoints Richard A. Meier to Board of Directors
Accuray announced that Richard A. Meier has been appointed as a member of Accuray's board of directors, effective immediately, and will serve on the company's Compensation Committee. Meier brings more than 30 years of executive leadership experience across the healthcare and medical technology sectors. His prior leadership roles include CEO and director of TwinMed; CEO and director of Rockley Photonics Holdings Limited; CFO of IntersectENT.
Accuray Shareholders Approve TCW Transactions
Accuray Incorporated announced that stockholders approved all proposals presented at the company's Special Meeting of Stockholders held on October 6, enabling Accuray to complete its previously announced transactions with TCW Asset Management Company, the company's primary lender and largest shareholder. The approved proposals will enable Accuray to complete the previously announced TCW financing transaction. The approved proposals included the issuance of shares of common stock in accordance with Nasdaq Listing Rule 5635 in connection with the company's previously announced financing transaction, an increase in the number of authorized shares of common stock, and a reverse stock split of the company's common stock, at a ratio ranging from any whole number between 1-for-15 and 1-for-40 determined by Accuray's board of directors in its discretion. The board of directors maintains the discretion to select any whole number ratio within the approved range and the exact timing of the reverse stock split. The board of directors is evaluating market conditions and other relevant factors in determining the appropriate ratio and timing for the reverse split.
Accuray Partners with Samsung to Enhance CyberKnife Imaging Technology
Accuray Incorporated (ARAY) announced that it had entered into agreements with Samsung HME America (SSNLF) to pursue advanced volumetric imaging capabilities for the CyberKnife System. The announcement coincides with the American Society of Radiation Oncology, ASTRO, Annual Meeting in Boston, Massachusetts, where the companies are highlighting their collaboration. The collaboration represents another example of Accuray's strategy to address customer priorities through targeted partnerships that bring together complementary expertise.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.







